Two recently introduced drugs offer additional treatment options for narcolepsy in Europe and the Unite States: the histamine H3 receptor antagonist/inverse agonist pitolisant for EDS and cataplexy, and the dopamine and norepinephrine reuptake blocker solriamfetol for EDS (15, 18, 32). The gene discussed is HRH3; the disease is Ehlers-Danlos syndrome.